Bionano Genomics, Inc.
BNGO
$4.08
-$0.02-0.49%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -34.83% | -10.29% | 18.26% | 30.51% | 29.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.83% | -10.29% | 18.26% | 30.51% | 29.04% |
| Cost of Revenue | 121.02% | -18.38% | 11.23% | 29.22% | 21.38% |
| Gross Profit | -407.24% | 12.00% | 36.43% | 35.07% | 51.96% |
| SG&A Expenses | -61.99% | -57.09% | -21.67% | -16.05% | 17.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.57% | -50.78% | -20.28% | -9.57% | 14.94% |
| Operating Income | 37.03% | 59.73% | 27.99% | 18.81% | -11.77% |
| Income Before Tax | 60.70% | 58.34% | 15.25% | -19.13% | -254.07% |
| Income Tax Expenses | -38.46% | -21.21% | -169.23% | -101.99% | 39.29% |
| Earnings from Continuing Operations | 60.69% | 58.31% | 15.36% | -13.48% | -253.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.69% | 58.31% | 15.36% | -13.48% | -253.88% |
| EBIT | 37.03% | 59.73% | 27.99% | 18.81% | -11.77% |
| EBITDA | 47.46% | 64.44% | 30.13% | 22.84% | -8.54% |
| EPS Basic | 83.98% | 80.56% | 51.53% | 15.46% | -192.91% |
| Normalized Basic EPS | 73.47% | 77.29% | 57.41% | -2.30% | 8.20% |
| EPS Diluted | 83.98% | 80.56% | 51.22% | 15.33% | -192.91% |
| Normalized Diluted EPS | 73.47% | 77.29% | 57.41% | -2.30% | 8.20% |
| Average Basic Shares Outstanding | 145.34% | 114.56% | 74.60% | 34.24% | 20.82% |
| Average Diluted Shares Outstanding | 145.34% | 114.56% | 74.60% | 34.24% | 20.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
